20 suspended. 20 Phase 2, 6 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 20 | Suspended 20 |
| Phase 1 | 6 | Suspended 6 |
Follow Lymphatic Diseases: new trials by email Literature Review of Lymphatic Diseases trials Research Report on Lymphatic Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pyronaridine in Acute Myeloid Leukemia (AML) Pyronaridine Tetraphosphate - Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL) | Phase 2 | Suspended | Armaceutica, Inc. | 200 | 2028-02-21 | 2026-10-19 |
| Evaluation of Novel Iron-based Lymphatic Mapping Agent, Magtrace, for Delayed Sentinel Lymph Node Biopsy (SLNB) in Ductal Carcinoma In-Situ (DCIS) Magtrace - Ductal Carcinoma in Situ | Phase 2 | Suspended | University of Florida | 30 | 2026-10-01 | 2026-09-11 |
| Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombinant Erwinia Asparaginase (JZP458) for the Treatment of Newly Diagnosed Ph Negative B-Acute Lymphoblastic Leukemia or T Acute Lymphoblastic Leukemia Asparaginase Erwinia chrysanthemi, Biospecimen Collection, Bone Marrow Collection - B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative, T Acute Lymphoblastic Leukemia | Phase 2 | Suspended | University of Washington | 30 | 2026-05-08 | 2026-09-29 |
| Phase 2 Study to Assess the Safety and Efficacy of Subcutaneous Blinatumomab in Patients With Measurable Residual Disease Positive B-cell Acute Lymphoblastic Leukemia Blinatumomab - Phase 2 Study, Blinatumomab | Phase 2 | Suspended | M.D. Anderson Cancer Center | 40 | 2026-04-21 | 2026-10-08 |
| ABBA CORD: dCBT w/ Abatacept for aGVHD Prophylaxis Cyclophosphamide, Fludarabine, Thiotepa - Acute Myelogenous Leukemia, Acute Lymphatic Leukemia | Phase 2 | Suspended | Leland Metheny | 20 | 2026-04-08 | 2026-09-10 |
| ST-067 in Combination With CD19-Directed CAR T-Cell Therapy (Liso-cel) in Relapsed/Refractory Large B-Cell Lymphoma Vevoctadekin, Bone Marrow Aspiration, Bone Marrow Biopsy - Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Phase 1 / Phase 2 | Suspended | Fred Hutchinson Cancer Center | 33 | 2025-12-27 | 2026-09-11 |
| HEARTS Trial for Thoracic Cancers MRgART, LINAC - Non-Small Cell Lung Cancer (Stage III), Esophageal Cancer Stage I-III | Phase 2 | Suspended | University of Wisconsin, Madison | 60 | 2025-10-08 | 2026-10-30 |
| A Phase 1b/2 Study of Intravenous Brincidofovir in Patients With Relapsed or Refractory Lymphoma and Relapsed or Refractory Extranodal Natural Killer/T-cell Lymphoma Brincidofovir - Relapsed or Refractory Lymphoma Including ENKL | Phase 1 / Phase 2 | Suspended | SymBio Pharmaceuticals | 43 | 2025-06-09 | 2026-02-05 |
| Epcoritamab and Tazemetostat for the Treatment of Relapsed or Refractory Grade I-IIIa Follicular Lymphoma Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography - Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma | Phase 2 | Suspended | City of Hope Medical Center | 33 | 2025-03-11 | 2026-01-21 |
| A Phase II Clinical Trial to Evaluate Safety and Efficacy of XmAb20717 in Advanced Rare Cancers XmAb20717 - Microsatellite High Cancers, Peritoneal Mesothelioma | Phase 2 | Suspended | M.D. Anderson Cancer Center | 140 | 2022-08-05 | 2026-10-13 |
| A Study of MT-101 in Subjects With CD5+ Relapsed/Refractory TCL MT-101, MT-101 + Conditioning (Lymphodepleting) Chemotherapy - Lymphoma, T-Cell, Peripheral, Lymphoma, T-Cell, Cutaneous | Phase 1 / Phase 2 | Suspended | Myeloid Therapeutics | 40 | 2021-12-15 | 2023-11-13 |
| Ph I/II Study of E7777 Prior to CAR-T for R/R LBCL E7777, Fludarabine, Cyclophosphamide - DLBCL, Diffuse Large B Cell Lymphoma | Phase 1 / Phase 2 | Suspended | Masonic Cancer Center, University of Minnesota | 30 | 2021-06-09 | 2026-01-15 |
| HM-178: Assessing Methods for Improvement in Methotrexate Toxicity Management and Detection of Central Nervous System Involvement of Aggressive Lymphoma Glucarpidase - Lymphoma | Phase 2 | Suspended | Fox Chase Cancer Center | 3 | 2021-04-16 | 2024-03-22 |
| Zanubrutinib Combined With Standard Chemotherapy in the Treatment for Patients With Diffuse Large B Cell Lymphoma Rituximab, Zanubrutinib, Cyclophosphamide - Diffuse Large B Cell Lymphoma, CD79A Gene Mutation | Phase 2 | Suspended | Henan Cancer Hospital | 59 | 2020-12-25 | 2025-04-25 |
| Nivolumab and Combination Chemotherapy in Treating Participants With Diffuse Large B-Cell Lymphoma Cyclophosphamide, Doxorubicin Hydrochloride, Nivolumab - Aggressive Non-Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma | Phase 1 / Phase 2 | Suspended | Northwestern University | 30 | 2018-11-20 | 2022-08-15 |
| Brentuximab Vedotin and BeEAM High-dose Chemotherapy in Lymphomas Brentuximab Vedotin, BeEAM Regimen - Lymphoma | Phase 1 / Phase 2 | Suspended | Insel Gruppe AG, University Hospital Bern | 20 | 2018-09-01 | 2025-03-30 |
| Pembrolizumab in Neoplasms or Lymphomas Pembrolizumab - Lymphoma, Histiocytic Sarcoma | Phase 2 | Suspended | Dana-Farber Cancer Institute | 18 | 2017-12-07 | 2026-08-06 |
| Oshadi D & Oshadi R Combined With Salvage Chemotherapy for Relapsed Acute Myeloid Leukemia or Lymphoid Leukemia Patients Oshadi D & Oshadi R;, salvage therapy cytosar and mitoxantrone - Acute Myeloid Leukemia, Lymphoid Leukemia | Phase 2 | Suspended | Oshadi Drug Administration | 15 | 2017-01-01 | 2018-04-18 |
| Phase II Clinical Trial of Alemtuzumab to Treat B-cell Chronic Lymphocytic Leukemia Alemtuzumab - B-cell Chronic Lymphocytic Leukemia | Phase 2 | Suspended | Shanghai Zhangjiang Biotechnology Limited Company | 120 | 2011-07-01 | 2022-06-21 |
| Study for Safety and Efficacy Evaluation of Imatinib Mesylate in Children With Acute Lymphoblastic Leukemia (ALL) Philadelphia Chromosome-positive (Ph+) Imatinib Mesylate - Acute Lymphoblastic Leukemia (ALL) Philadelphia Chromosome-positive (Ph+) | Phase 2 | Suspended | Renato Melaragno | 20 | 2013-03-26 |
Lymphoma (5) · Lymphoma, Large B-Cell, Diffuse (4) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (4) · Leukemia, Myeloid, Acute (3) · Hodgkin Disease (2) · Lymphoma, T-Cell (2) · Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (2) · Burkitt Lymphoma (1) · Carcinoma, Intraductal, Noninfiltrating (1) · Carcinoma, Neuroendocrine (1) · Carcinoma, Non-Small-Cell Lung (1) · Congenital Abnormalities (1) · Dendritic Cell Sarcoma, Follicular (1) · Dendritic Cell Sarcoma, Interdigitating (1) · Epstein-Barr Virus Infections (1)
Hemic and Lymphatic Diseases (20) · Neoplasms by Histologic Type (20) · Neoplasms (19) · Immune System Diseases (18) · Immunoproliferative Disorders (18) · Lymphoproliferative Disorders (18) · Hematologic Diseases (8) · Lymphoma (8) · Lymphoma, Non-Hodgkin (8) · Leukemia (7) · Leukemia, Lymphoid (7) · Lymphoma, B-Cell (5) · Disease Attributes (3) · Leukemia, Myeloid (3)
Cyclophosphamide (5) · Magnetic Resonance Spectroscopy (3) · Prednisone (3) · Rituximab (3) · Vincristine (3) · Biopsy (2) · CT-P10 (2) · Doxorubicin (2) · Specimen Handling (2) · deltacortene (2) · fludarabine (2) · prednylidene (2) · Abatacept (1) · Alemtuzumab (1) · Antineoplastic Agents (1)
M.D. Anderson Cancer Center (2) · Armaceutica, Inc. (1) · City of Hope Medical Center (1) · Dana-Farber Cancer Institute (1) · Fox Chase Cancer Center (1) · Fred Hutchinson Cancer Center (1) · Henan Cancer Hospital (1) · Insel Gruppe AG, University Hospital Bern (1) · Leland Metheny (1) · Masonic Cancer Center, University of Minnesota (1) · Myeloid Therapeutics (1) · Northwestern University (1) · Oshadi Drug Administration (1) · Renato Melaragno (1) · Shanghai Zhangjiang Biotechnology Limited Company (1)
United States (13) · China (3) · Japan (1) · Senegal (1) · Singapore (1) · Switzerland (1)
Alexandre V. Hirayama, MD (1) · Arvind Nageshwara Dasaru, MD (1) · Carri Glide-Hurst, PhD, DABR, FAAPM (1) · Elias Jabbour, MD (1) · Eric Jacobsen, MD (1) · Jun Zhu, M.D. (1) · Leland Metheny, MD (1) · Lisa Spiguel, MD (1) · Michele Gerber, MD, MPH (1) · Moshe Gatt, MD (1) · Reem Karmali, MD (1) · Renato J Aguilera, PhD (1) · Ryan D. Cassaday, MD (1) · Swetha Kambhampati (1) · Thomas Pabst, MD (1)
PMID 32871584, PMID 38022532, PMID 40706069, PMID 41117344
P30CA033572 (1), P30CA060553 (1), R01HL153720 (1)